VistaGen Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Vistagen Therapeutics

07/02/2023 23:29

* VistaGen Therapeutics Inc  VTGN.OQ  reported a quarterly
adjusted loss of 5 cents​​ per share for the quarter ended in
December. The mean expectation of three analysts for the quarter
was for a loss of 7 cents per share.
    * Revenue fell 49.7% to $180.00 thousand from a year ago;
analysts
expected $155.00 thousand. 
    * VistaGen Therapeutics Inc's reported EPS for the quarter
was a
loss of 5 cents​.
    * The mean earnings estimate of analysts had fallen by
about 16.7%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * VistaGen Therapeutics Inc shares had risen by 142.2% this
quarter.
    * The company reported a quarterly loss of $9.76 million.
    * Wall Street's median 12-month price target for VistaGen
Therapeutics Inc is $0.20 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data February
7 at 11:29 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.07          -0.05          Beat
 Sep. 30 2022      -0.07          -0.08          Missed
 Jun. 30 2022      -0.07          -0.10          Missed
 Mar. 31 2022      -0.06          -0.09          Missed